Skip to main content
. 2023 May 16;31(7):2132–2153. doi: 10.1016/j.ymthe.2023.05.009

Table 1.

Patient characteristics

Sample ID Donor ID Gender Age (years) Treatment status Treatment history
MCL 1 BBX1000- N3122064314101121SH male 50 newly diagnosed N/A
MCL 2 BBX1000-E7120374102050415SH male 65 treatment naive N/A
MCL 3 BBX1000-SC120904028062321SH male 68 BR (cycle 1, day 1) prior lines of therapy: ibrutinib, rituximab, BR, rituximab, stem cell transplant, HiDAC-R, R-CHOP, zanubrutinib

BR, bendamustine + rituximab; HiDAC-R, high-dose cytarabine + rituximab; N/A, not applicable or not available; R-CHOP, rituximab + cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin).